Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7203331 | 0.86 | CPB2 (0.44) | CNR2CPB2CYP1A2 | |
| SCHEMBL7203547 | 0.84 | ANPEP (0.38) | CNR2ANPEPFOLH1CA1CA2 | |
| SCHEMBL7599625 | 0.82 | ANPEP (0.37) | CNR2ANPEPFOLH1CA1CA2 | |
| SCHEMBL7205241 | 0.82 | ANPEP (0.37) | CNR2ANPEPFOLH1CA1CA2 | |
| SCHEMBL7198286 | 0.82 | FOLH1 (0.39) | CNR2ANPEPFOLH1CA1CA2 | |
| SCHEMBL12534428 | 0.81 | ANPEP (0.36) | CNR2ANPEPFOLH1CA1CA2 | |
| SCHEMBL1704900 | 0.79 | FOLH1 (0.46) | FOLH1CA1CA2CPB2 | |
| SCHEMBL12890801 | 0.79 | ANPEP (0.39) | CNR2ANPEPFOLH1CA1CA2 | |
| SCHEMBL22291193 | 0.79 | ANPEP (0.39) | CNR2ANPEPFOLH1CA1CA2 | |
| SCHEMBL22291195 | 0.79 | ANPEP (0.39) | CNR2ANPEPFOLH1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602910-B2 | Treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine | ILEX ONCOLOGY, INC. | 2003-08-05 | — | — | US | disclosed |
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | ILEX ONCOLOGY, INC. (US) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045663-A1 | D-enantiomer of DFMO and methods of use therefor | DHODH, DDT, HADHB | CNR2 2678/4885ANPEP 1519/4885FOLH1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.